Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04055493
Title Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC (ADAPTcycle)
Recruitment Recruiting
Gender female
Phase Phase III
Variant Requirements No
Sponsors West German Study Group
Indications

Her2-receptor negative breast cancer

Therapies

Ribociclib

Age Groups: senior | adult
Covered Countries DEU


No variant requirements are available.